Dataset Information
Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran.
Ontology highlight
ABSTRACT: Background and purpose
Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.Methods
We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab.Results
In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging.Conclusions
In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.
SUBMITTER: Held V
PROVIDER: S-EPMC5121568 | biostudies-literature | 2016 Sep-Dec
REPOSITORIES: biostudies-literature
Publications
Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran.
Case reports in neurology 20160901 3
<h4>Background and purpose</h4>Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.<h4>Methods</h4>We report two cases of patients on dabigatran with acute int ...[more]
